Evidence map›Paper›PMID 40080721›Full record

ReviewOncotarget2025

Signaling pathway dysregulation in breast cancer.

Dinara Ryspayeva, Attila A Seyhan, William J MacDonald, Connor Purcell, Tyler J Roady, Maryam Ghandali, Nataliia Verovkina, Wafik S El-Deiry, Martin S Taylor, Stephanie L Graff

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dinara RyspayevaLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Attila A SeyhanLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
William J MacDonaldLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Connor PurcellLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Tyler J RoadyLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Maryam GhandaliLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Nataliia VerovkinaLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Wafik S El-DeiryLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02903, USA.
Martin S TaylorDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02903, USA.
Stephanie L GraffLegorreta Cancer Center at Brown University, RI 02903, USA.

Funding

Elucidating structural, mechanistic, and allosteric determinants of mTOR Complex 2 (mTORC2) signaling.K08DK129824 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI TAYLOR, MARTIN S · 2021 to 2025
$853k
NIDDK NIH HHS K08 DK129824
6 · The paper itself

Abstract

This article provides a comprehensive analysis of the signaling pathways implicated in breast cancer (BC), the most prevalent malignancy among women and a leading cause of cancer-related mortality globally. Special emphasis is placed on the structural dynamics of protein complexes that are integral to the regulation of these signaling cascades. Dysregulation of cellular signaling is a fundamental aspect of BC pathophysiology, with both upstream and downstream signaling cascade activation contributing to cellular process aberrations that not only drive tumor growth, but also contribute to resistance against current treatments. The review explores alterations within these pathways across different BC subtypes and highlights potential therapeutic strategies targeting these pathways. Additionally, the influence of specific mutations on therapeutic decision-making is examined, underscoring their relevance to particular BC subtypes. The article also discusses both approved therapeutic modalities and ongoing clinical trials targeting disrupted signaling pathways. However, further investigation is necessary to fully elucidate the underlying mechanisms and optimize personalized treatment approaches.

Indexed as

Breast NeoplasmsSignal TransductionAnimalsFemaleHumansMolecular Targeted TherapyMutationbreast cancerclinical trialsoncogenic pathwayssignal dysregulation in cancertherapeutic approaches

Identifiers

PMID40080721
PMCPMC11906143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.